NasdaqCM - Delayed Quote USD

Addex Therapeutics Ltd (ADXN)

18.74

-0.54

(-2.80%)

At close: April 23 at 4:00 PM EDT

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporat

GlobeNewswire 4 days ago

ADXN
-2.80%
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation

GlobeNewswire 5 days ago

ADXN
-2.80%
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:0

GlobeNewswire 12 days ago

ADXN
-2.80%
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, an

GlobeNewswire 20 days ago

ADXN
-2.80%
Addex to Present at the Bio-Europe Spring 2024 Conference

Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain. Dr. Robert Lütjens, Head of Discovery – Biology, will also be attending this event. In his presentation, Mr Dyer will provide a corporate update and discuss recent development

GlobeNewswire last month

ADXN
-2.80%
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at

GlobeNewswire 2 months ago

ADXN
-2.80%
Addex to Present at the Swiss Equities Baader Conference

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex’s CNS pipeline. Present

GlobeNewswire 3 months ago

ADXN
-2.80%
Addex to Present at Biotech Showcase™ 2024

CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024. In his presentation, scheduled for Monday January 8, 2024 at 4:30 PM PT (01:3

GlobeNewswire 3 months ago

ADXN
-2.80%
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors at its Extraordinary General Meeting (EGM) held on December 19, 2023. The votes represented 30.07% of the Company's outsta

GlobeNewswire 4 months ago

ADXN
-2.80%
Addex Creates Treasury Shares

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the Company”), announced today that 15,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s capital band, are li

GlobeNewswire 4 months ago

ADXN
-2.80%
Addex Reports Q3 2023 Financial Results and Provides Corporate Update

ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024mGlu2 NAM cognition program receives a €4 million Eurostars grantCHF 4.8M ($5.2M) of cash and cash equivalents at September 30, 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 29, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today

GlobeNewswire 4 months ago

ADXN
-2.80%
Addex Convenes Extraordinary General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that an Extraordinary General Meeting is convened and will take place on Tuesday December 19, 2023, at 11:00 am CET at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). The items in the agenda will be the followi

GlobeNewswire 4 months ago

ADXN
-2.80%
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a tele

GlobeNewswire 4 months ago

ADXN
-2.80%
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with le

GlobeNewswire 5 months ago

ADXN
-2.80%
Addex Regains Nasdaq Listing Compliance

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable cr

GlobeNewswire 5 months ago

ADXN
-2.80%
Addex Announces Participation in the Bio-Europe 2023 Conference

Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference (November 6 – 8, 2023) in Munich, Germany. A pre-recorded presentation, in which Mr. Dyer provides a corporate update and discusses recent dev

GlobeNewswire 5 months ago

ADXN
-2.80%
Addex Completes ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the Company’s previously disclosed change to its American Depositary Shares (“ADSs”) to ordinary share ratio has been accepted by Nasdaq and will be effective on October 23, 2023. The ratio will change from one (1) ADS to six (6) ordinary sha

GlobeNewswire 6 months ago

ADXN
-2.80%
Addex Announces Plan to Implement ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”) from the current ADS Ratio of one (1) ADS to six (6) ordinary shares to a new ADS Ratio of one (1) ADS to one hundred and twenty (

GlobeNewswire 6 months ago

ADXN
-2.80%
Addex Therapeutics focused on securing new partnerships to fund promising treatments

Addex Therapeutics co-founder and CEO Tim Dyer speaks to Thomas Warner from Proactive about the work that the central nervous system-focused clinical-stage pharmaceutical company has been doing in ...

News Direct 6 months ago

ADXN
-2.80%
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 (mGlu2) rece

GlobeNewswire 6 months ago

ADXN
-2.80%

Performance Overview

Return	ADXN	MSCI WORLD
YTD	+209.75%	+4.93%
1-Year	+24.93%	+17.80%
3-Year	-91.16%	+13.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Addex Therapeutics Ltd (ADXN)

Addex to Present at the Swiss Biotech Day 2024

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex to Present at the Bio-Europe Spring 2024 Conference

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Addex to Present at the Swiss Equities Baader Conference

Addex to Present at Biotech Showcase™ 2024

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Addex Creates Treasury Shares

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Addex Convenes Extraordinary General Meeting

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

Addex Announces Participation in the Bio-Europe 2023 Conference

Addex Completes ADS Ratio Change

Addex Announces Plan to Implement ADS Ratio Change

Addex Therapeutics focused on securing new partnerships to fund promising treatments

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Performance Overview